pharmacie et médicaments – Attractivité de l'accès précoce aux médicaments innovants

This written question concerns the attractiveness of early access schemes for innovative medicines in France. It seeks to understand the current framework and potential improvements. The question addresses the pharmaceutical industry, healthcare providers, and patients who could benefit from faster access to new treatments.